As proposed yesterday by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention recommends that starting this fall all infants under 8 months old receive one dose of the new long-acting monoclonal antibody nirsevimab to prevent respiratory syncytial virus, and that certain infants 8-19 months old at risk for severe disease receive one dose in their second RSV season. The Food and Drug Administration last month approved the product for use in these age groups. An estimated 58,000 to 80,000 U.S. children under age 5, mostly infants, are hospitalized each year due to RSV. 

“RSV is the leading cause of hospitalizations for infants and older babies at higher risk and today we have taken an important step to make this life saving product available,” said CDC director Mandy Cohen, M.D.
 

Related News Articles

Headline
A study published by JAMA Aug. 13 found that a two-dose antibiotic treatment could be just as effective as traditional long-term IV therapy for treating…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The AHA and Federation of American Hospitals Aug. 8 filed an amicus brief in the U.S. District Court for the Eastern District of Texas in support of the U.S.…
Headline
President Trump Aug. 7 issued an executive order, “Improving Oversight of Federal Grantmaking,” requiring government agencies to review new and discretionary…
Headline
The Centers for Medicare & Medicaid Services July 15 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
Ochsner Health's Stephen Saenz, sepsis program manager, and Teresa Arrington, director of robust process improvement for quality and patient safety, reveal how…